IL6 and neoplasm: These preclinical results indicate that targeted inhibition of IL‐6 may enhance the efficacy of anti‐PD‐L1 in PDAC (Table 5).78 Other inhibitory factors in the tumor microenvironment, such as TGF‐β80 and PGE275, 81 and its inhibitors, are summarized in Table 5.